Deng, Wei
Mayo Clinic
Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY;
Citations 1
Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
Tritchler, David , Starr, Mark D. , Brady, John C. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , Gray, Heidi J. , Boente, Matthew, Deng, Wei , Burger, Robert A. , Birrer, Michael J. , Secord, Angeles Alvarez , Liu, Yingmiao , Lankes, Heather A. , O’Malley, David M. , Bakkum‐Gamez, Jamie N. , Fujiwara, Keiichi , Deng, Wei, Nixon, Andrew B.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5521-5521
